Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital Plc LSE:TEK London Ordinary Share GB00BKXGY798 ORD �0.004
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.00 369,717 12:41:41
Bid Price Offer Price High Price Low Price Open Price
10.50 11.50 11.00 10.50 11.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 5.36 3.57 8.08 1.3 10
Last Trade Time Trade Type Trade Size Trade Price Currency
16:21:28 O 2,721 11.30 GBX

Tekcapital (TEK) Latest News

More Tekcapital News
Tekcapital Takeover Rumours

Tekcapital (TEK) Discussions and Chat

Tekcapital (TEK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-07-08 15:21:2911.302,721307.47O
2020-07-08 14:46:5011.1911,7061,309.90O
2020-07-08 13:51:1411.194,415494.04O
2020-07-08 13:44:2510.7310,9501,174.39O
2020-07-08 13:26:0910.7350153.73O
View all Tekcapital trades in real-time

Tekcapital (TEK) Top Chat Posts

DateSubject
08/7/2020
09:20
Tekcapital Daily Update: Tekcapital Plc is listed in the Technology Hardware & Equipment sector of the London Stock Exchange with ticker TEK. The last closing price for Tekcapital was 11p.
Tekcapital Plc has a 4 week average price of 10p and a 12 week average price of 9.75p.
The 1 year high share price is 23p while the 1 year low share price is currently 3.75p.
There are currently 87,778,042 shares in issue and the average daily traded volume is 452,537 shares. The market capitalisation of Tekcapital Plc is £9,655,584.62.
08/4/2020
17:42
bountyhunter: Something about Belluscura should be in the header or potential investors may not find it without a bit of digging! Https://mobile.twitter.com/Belluscura/status/1246686048920502272 Https://mobile.twitter.com/Belluscura Https://www.tekcapital.com/ourportfolio/ Https://uk.advfn.com/stock-market/london/tekcapital-TEK/share-news/Tekcapital-plc-Belluscura-plc-filing-of-a-patent/81999003
07/4/2020
11:08
bountyhunter: Something about this should be in the header or potential investors may not be aware! Https://mobile.twitter.com/Belluscura/status/1246686048920502272 Https://mobile.twitter.com/Belluscura Https://www.tekcapital.com/ourportfolio/ Https://uk.advfn.com/stock-market/london/tekcapital-TEK/share-news/Tekcapital-plc-Belluscura-plc-filing-of-a-patent/81999003
23/3/2020
08:46
timberwolf3: Good news, no wonder the share price is reacting. hTTps://www.belluscura.com/new-fda-guidance-provides-a-policy-designed-to-expand-the-availability-of-respiratory-devices-including-oxygen-concentrators-during-the-covid-19-pandemic/?fbclid=IwAR0X1z9sPLHTwo2-ICoPWX77qXe3F-OdkC3Zyfo-dYjZNkxN_rf6bF0-CHo
20/3/2020
08:38
philjeans: Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company. Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the share price That means 5.5p equates to a 15 PE profit rate of £300k. Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed. 1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it. 2015 data and the problem is growing. Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million. So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it. So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price.
17/3/2020
08:39
superg1: iam You can't call a £4 mill MC cap over-priced imo under the circs of where they are now. Certain parts are jun k imo but the salt is gaining traction, products launched 97.5% owned. Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company. Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the share price That means 5.5p equates to a 15 PE profit rate of £300k. Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed. 1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it. 2015 data and the problem is growing. Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million. So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it. So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price. Just my view. Cold and flu viruses for such sufferers severely compound their illness.
10/1/2020
13:19
pjj71: 50p in 2017 to 6p in 2020 is a battering of note to the share price...
20/12/2019
12:49
cokehookerscars: Other than the fall in share price, the meaningless news is the most frustrating thing. I've caught this falling knife for a while now and am getting fed up of the useless updates. 17 I got in at :-( then 12, 9 and 5.6. Of course with a few projects becoming blockbusters these prices could be made to look small but at the moment I can't gauge whether I think this is going to 1p or 20p in the next 12 months as the info they provide gives us nothing. This is a wildly speculative investment to be fair but more transparency would be nice.
02/9/2019
14:03
pjj71: all that promotion on the musical glasses just resulted in more confetti placings hence the share price being a fraction of its highs... if they had managed a rank higher than 1,500,000 in the top sellers in the height of summer last week then I would be more encouraging on marketing spend... however the trend is usually your friend...
02/9/2019
07:31
cf456: "pleased to announce that there are now eleven companies testing MicroSalt(R), a low sodium salt developed by the Group's portfolio company Salarius for possible incorporation into their snack products. Additionally, Salarius has received a registered trademark on SaltMe!(R) for its forthcoming full-flavour, low sodium snacks which it intends to launch in H1 2020." "Our first customer has placed their third order for MicroSalt(R) and we have significant prospective customer interest" hTTps://uk.advfn.com/stock-market/london/tekcapital-TEK/share-news/Tekcapital-plc-Portfolio-Company-Update/80640410
13/6/2019
08:54
someuwin: Hybridan 05/06/2019: An IP business with a difference Tekcapital Plc commercialises university intellectual property (IP), a process known as technology transfer, both for its own portfolio and as a service for client companies. Its unique strength lies in the impressive size of its university IP network, the world’s largest, which incorporates some 80% of university-developed IP, from 4,500 institutions in 160 countries. The Company has over the past three years built up an exciting portfolio of four disruptive companies sourced from its network. They offer investors diversified exposure to the growing food technology, eyewear technology, autonomous vehicle and medical equipment markets in the US and UK. All have proprietary IP, experienced leadership and are showing strong traction, characteristics Tekcapital requires in all its portfolio companies, and it is its intention to pay a special dividend to investors upon exit. In addition to its portfolio, the Company has a growing services division, where revenues in the FY to November 30, 2018 rose by 28% to $1.04m, 15% of total revenues. We are encouraged that it is the Company’s prudent aim that revenue from the division, which currently covers just under half of all corporate expenses, will over the next few years cover all costs, enabling more capital to be used for investment purposes. This dual strategy, which differentiates Tekcapital from other IP commercialisation companies such as IP Group, Allied Minds and Mercia Technologies, appears to be yielding fruit. In 2018, the Company’s net asset value increased for a third year by 51% to a record US$16.1m, boosted by an 88% increase in the portfolio’s valuation to US$13.7m, and profit after tax rose 10% to US$4.6m. NAV per share was US$0.30, or 23.75p, more than double the current share price, underlining the potential for investors. We believe Tekcapital is a compelling opportunity whose strategy means it is not solely dependent on the success of its investee companies, a fact that does not appear to be fully recognised by the market. Furthermore, it is well poised to benefit from growth in licencing revenues from university spin-outs, which in 2017 reached a record of over US$3bn in the US, according to the Association of University Technology Managers. With the shares trading a touch over one times last year’s earnings, no debt in the business and at a very considerable discount to NAV, we urge investors to take a close look at the opportunity.
Tekcapital share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
TEK
Tekcapital
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200709 00:16:34